Versican Plus BbPI IN nasal drops, lyophilisate and solvent for suspension for dogs

Authorised

- Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
- Bordetella bronchiseptica, strain MSLB 3096, Live

Product identification

Medicine name:
Versican Plus BbPi IN gouttes nasales, lyophilisat et solvant pour suspension pour chiens
Versican Plus BbPI IN nasal drops, lyophilisate and solvent for suspension for dogs

Active substance:
Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
Bordetella bronchiseptica, strain MSLB 3096, Live

Target species:
Dog

Route of administration:
Nasal use

Product details

Active substance and strength:

Canine parainfluenza virus, strain CPiV-2-Bio 15, Live
3.50 log10 50% tissue culture infectious dose / 1.00 Dose

Bordetella bronchiseptica, strain MSLB 3096, Live
8.00 log10 colony forming unit(s) / 1.00 Dose

Pharmaceutical form:
Lyophilisate and solvent for oral suspension

Withdrawal period by route of administration:
Nasal use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AF01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Luxembourg

Available in:
Luxembourg

Package description:
(ID2): 1 Box with (10 Vial (Glass) with 1 Dose and 10 Vial (Glass) with 0.5 millilitre(s)) (10.0 Dose, 5.0 millilitre(s))
(ID1): 1 Box with (5 Vial (Glass) with 1 Dose and 5 Vial (Glass) with 0.5 millilitre(s)) (5.0 Dose, 2.5 millilitre(s))

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)

Marketing authorisation holder:
Zoetis Belgium

Marketing authorisation date:
7/04/2020

Manufacturing sites for batch release:
Bioveta a.s.

Responsible authority:
Ministry Of Health And Social Security

Authorisation number:
V 087/20/04/1802

Date of authorisation status change:
28/01/2022

Reference member state:
Germany

Procedure number:
DE/V/0288/001

Concerned member states:
Austria Belgium Croatia Cyprus Czechia Estonia France Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Netherlands Poland Romania Slovakia Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

2613944-paren-20251101.pdf